<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Different ethnic groups with a high human leukocyte antigen (HLA)-A11 prevalence have been shown to experience a high rate of Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, and Epstein-Barr nuclear antigen (EBNA)-4 mutations </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:chebi fb="0" ids="53000">epitopes</z:chebi> 399-408 and 416-424 of EBNA-4 are major antigenic <z:chebi fb="0" ids="53000">epitopes</z:chebi> that elicit an HLA-A11 cytotoxic T lymphocyte (CTL) response to <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Mutations selectively involving one or more <z:chebi fb="0" ids="50319">nucleotide residues</z:chebi> in these <z:chebi fb="0" ids="53000">epitopes</z:chebi> affect the antigenicity of EBNA-4, because the mutant EBV strains are not recognized by the HLA-A11-restricted CTLs </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate these mutations in common EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> occurring in different populations, we studied the mutation rate of <z:chebi fb="0" ids="53000">epitopes</z:chebi> 399-408 and 416-424 of EBNA-4 in 25 cases of EBV-associated <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), nine cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 37 cases of EBV-associated gastric <z:mp ids='MP_0002038'>carcinoma</z:mp> (GC) from the United States, Brazil, and Japan </plain></SENT>
<SENT sid="4" pm="."><plain>We found one or more mutations in these two <z:chebi fb="0" ids="53000">epitopes</z:chebi> in 50% (6/12) of United States <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, 15% (2/13) of Brazilian <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, 50% (6/12) United States GC and 28% (7/25) Japanese GC, and 22% (2/9) of United States <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Similar mutations were found in 30% (3/10) of United States reactive, 0% (0/6) of Brazilian reactive, and 25% (2/8) Japanese reactive tissues </plain></SENT>
<SENT sid="6" pm="."><plain>The most frequent amino acid substitutions were virtually identical to those seen in previously reported isolates from EBV-associated nasopharyngeal <z:mp ids='MP_0002038'>carcinomas</z:mp> and Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> occurring in high prevalence HLA-A11 regions </plain></SENT>
<SENT sid="7" pm="."><plain>However, only 2/28 (7%) mutations occurred in HLA-A11-positive patients </plain></SENT>
<SENT sid="8" pm="."><plain>Our studies suggest that: 1) EBNA-4 mutations are a common phenomenon in EBV-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, GC, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-<z:hpo ids='HP_0002665'>lymphoma</z:hpo>; 2) the mutation rate does not vary in these geographic areas and ethnic groups; 3) EBNA-4 mutations in EBV-associated United States and Brazilian <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, United States and Japanese GC, and United States <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are not related to patients' HLA-A11 status </plain></SENT>
</text></document>